187 related articles for article (PubMed ID: 12377655)
1. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
von Rohr A; Schmitz SF; Tichelli A; Hess U; Piguet D; Wernli M; Frickhofen N; Konwalinka G; Zulian G; Ghielmini M; Rufener B; Racine C; Fey MF; Cerny T; Betticher D; Tobler A;
Ann Oncol; 2002 Oct; 13(10):1641-9. PubMed ID: 12377655
[TBL] [Abstract][Full Text] [Related]
2. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
Juliusson G; Heldal D; Hippe E; Hedenus M; Malm C; Wallman K; Stolt CM; Evensen SA; Albertioni F; Tjønnfjord G
J Clin Oncol; 1995 Apr; 13(4):989-95. PubMed ID: 7707128
[TBL] [Abstract][Full Text] [Related]
4. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
Machii T; Chou T; Suzuki M; Ohe Y; Katagiri S; Kitano EK; Kitano K; Fujiyama Y; Izumi T; Shimazaki C; Nanba K; Ohashi Y; Kitani T;
Int J Hematol; 2005 Oct; 82(3):230-5. PubMed ID: 16207596
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
Nielsen OJ; Hippe E; Priø TK; Juliusson G
Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Chadha P; Rademaker AW; Mendiratta P; Kim B; Evanchuk DM; Hakimian D; Peterson LC; Tallman MS
Blood; 2005 Jul; 106(1):241-6. PubMed ID: 15761021
[TBL] [Abstract][Full Text] [Related]
9. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
12. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Saven A; Burian C; Koziol JA; Piro LD
Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
[TBL] [Abstract][Full Text] [Related]
15. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
16. Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T; Levy I; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Dally N; Rouvio O; Shaulov A; Greenbaum U; Inbar M; Polliack A
Leuk Res; 2019 Jul; 82():24-28. PubMed ID: 31152919
[TBL] [Abstract][Full Text] [Related]
17. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC; Hsu Schmitz SF; Ratschiller D; von Rohr A; Egger T; Pugin P; Stalder M; Hess U; Fey MF; Cerny T
Br J Haematol; 1997 Nov; 99(2):358-63. PubMed ID: 9375754
[TBL] [Abstract][Full Text] [Related]
18. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
Saven A; Piro LD
Ann Intern Med; 1993 Aug; 119(4):278-83. PubMed ID: 8101069
[TBL] [Abstract][Full Text] [Related]
19. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.
Robak T; Jamroziak K; Gora-Tybor J; Blonski JZ; Kasznicki M; Dwilewicz-Trojaczek J; Wiater E; Zdunczyk A; Dybowicz J; Dmoszynska A; Wojtaszko M; Zdziarska B; Calbecka M; Kostyra A; Hellmann A; Lewandowski K; Stella-Holowiecka B; Sulek K; Gawronski K; Skotnicki AB; Nowak W; Zawilska K; Molendowicz-Portala L; Kloczko J; Sokolowski J; Warzocha K; Seferynska I; Ceglarek B; Konopka L
Blood; 2007 May; 109(9):3672-5. PubMed ID: 17209059
[TBL] [Abstract][Full Text] [Related]
20. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
